BRIEF—Lawmakers eye biosimilar-delay deals, but none are here yet

Pay-for-delay deals between pharma companies staving off generic competition have become a favorite target for lawmakers eager to be seen combating soaring drug costs and for antitrust enforcers who believe consumers are hurt when drug companies agree to postpone the introduction of generics.

In the USA, promoting such competition for biological therapies – or biosimilars - may be next on Washington's list, according to Life Sciences Law360, although none have yet been seen.